EN PL
REVIEW PAPER
Vascular rheumatology: atherosclerosis and cardiovascular disease in arthritis
 
More details
Hide details
 
Online publication date: 2012-09-07
 
 
Reumatologia 2012;50(4):336-344
 
KEYWORDS
ABSTRACT
Arthritides have been associated with accelerated atherosclerosis, increasing the risk of vascular disease. Traditional risk factors, as well as the role of systemic inflammation including activity of cytokines, chemokines, proteases, autoantibodies, adhesion molecules and others, have been implicated in the development of vascular diseases. Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been observed in rheumatoid arthritis (RA) and spondyloarthropathies (SpA).
Endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors.
In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have been published.
 
REFERENCES (57)
1.
Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126.
 
2.
Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99-106.
 
3.
Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
 
4.
Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
 
5.
Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7 Suppl 1: 328-331.
 
6.
Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
 
7.
Soltész P, Prohaszka Z, Fust G, et al. The autoimmune features of vasculopathies. Orv Hetil 2007; 148 Suppl 1: 53-57.
 
8.
Szekanecz Z. Pro-inflammatory cytokines in atherosclerosis. Isr Med Assoc J 2008; 10: 529-530.
 
9.
Szekanecz Z, Kerekes G, Der H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 2007; 1108: 349-358.
 
10.
Bodnar N, Kerekes G, Seres I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2010; 38: 723-729.
 
11.
Kerekes G, Szekanecz Z, Der H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35: 398-406.
 
12.
Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8: 663-667.
 
13.
Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61: 1571-1579.
 
14.
Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161-166.
 
15.
Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2009; 69: 325-331.
 
16.
Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009; 5: 677-684.
 
17.
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gonzalez-Juanatey C, Llorca J. Subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2008; 35: 2070-2071.
 
18.
Kerekes G, Soltész P, Der H, et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009; 1173: 814-821.
 
19.
Kerekes G, Soltész P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 28: 705-710.
 
20.
Tomasoni L, Sitia S, Borghi C, et al. Effects of treatment strategy on endothelial function. Autoimmun Rev 2011; 9: 840-844.
 
21.
Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2011; 9: 835-839.
 
22.
Szekanecz Z, Szanto S, Szabo Z, et al. Biologics – beyond the joints. Autoimmun Rev 2011; 9: 820-824.
 
23.
Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-3587.
 
24.
Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 289-297.
 
25.
Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873.
 
26.
Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33: 2425-2432.
 
27.
Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003; 30: 1403-1405.
 
28.
Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-763.
 
29.
Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009; 58: 316-318.
 
30.
Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121 (10 Suppl 1): S21-S31.
 
31.
Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence of anti-TNF-αlpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-379.
 
32.
Szekanecz Z, Koch AE. Cell-cell interactions in synovitis. Endothelial cells and immune cell migration. Arthritis Res 2000; 2: 368-373.
 
33.
Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Investig Med 1996; 44: 124-135.
 
34.
Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994;45:361-378.
 
35.
Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-369.
 
36.
Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008; 121 (10 Suppl 1): S3-S8.
 
37.
Szodoray P, Szabó Z, Kapitány A, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010;9:140-143.
 
38.
Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 1997;28:665-671.
 
39.
Kerekes G, Soltész P, Nurmohamed MT, et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012;8:224-234.
 
40.
Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
 
41.
Soltész P, Kerekes G, Dér H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011; 10: 416-425.
 
42.
Soltesz P, Der H, Kerekes G, et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009; 28: 655-662.
 
43.
Gerli R, Sherer Y, Bocci EB, et al. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 2007; 1108: 372-381.
 
44.
del Rincon I, Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 278-286.
 
45.
Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008; 38: 67-70.
 
46.
Atzeni F, Turiel M, Hollan I, et al. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2011; 9: 845-848.
 
47.
Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-365.
 
48.
Pieringer H. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45: 1319-1320.
 
49.
Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45: 283-286.
 
50.
Choe JY, Lee MY, Rheem I, et al. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008; 75: 548-553.
 
51.
Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47: 1203-1207.
 
52.
Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005; 19: 823-838.
 
53.
Giles JT, Post W, Blumenthal RS, Bathon JM. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2006; 2: 320-329.
 
54.
Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44: 1473-1482.
 
55.
Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55: 531-536.
 
56.
van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8: R151.
 
57.
Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/ macrophages. Arthritis Rheum 2008; 58: 3675-3683.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top